Cancer-Driver-Agnostic Targeting of Amplified Surface Proteins Identifies MPZL1 for Selective CAR-T Cell Therapy

Researchers developed a monoclonal antibody targeting myelin protein zero–like 1 (MPZL1)’s extracellular domain and engineered CAR-T cells that selectively eliminate MPZL1-positive cancer cells in vitro.